Cubist Systematic Strategies LLC purchased a new position in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 9,978 shares of the company’s stock, valued at approximately $228,000.

Several other institutional investors and hedge funds have also made changes to their positions in KALA. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $105,000. American International Group Inc. acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $122,000. California State Teachers Retirement System acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $301,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $313,000. Finally, Commonwealth Equity Services Inc acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $360,000. Institutional investors own 62.96% of the company’s stock.

Kala Pharmaceuticals Inc (KALA) opened at $12.95 on Wednesday. Kala Pharmaceuticals Inc has a 12 month low of $11.81 and a 12 month high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. The stock has a market cap of $313.74 and a price-to-earnings ratio of -7.12.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.14). equities analysts anticipate that Kala Pharmaceuticals Inc will post -2.22 earnings per share for the current fiscal year.

KALA has been the topic of several analyst reports. BidaskClub upgraded shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 29th. Wedbush restated an “outperform” rating and set a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $35.00 target price on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Kala Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $36.80.

TRADEMARK VIOLATION WARNING: “Cubist Systematic Strategies LLC Takes $228,000 Position in Kala Pharmaceuticals Inc (KALA)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/cubist-systematic-strategies-llc-takes-228000-position-in-kala-pharmaceuticals-inc-kala/1800897.html.

Kala Pharmaceuticals Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Want to see what other hedge funds are holding KALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kala Pharmaceuticals Inc (NASDAQ:KALA).

Institutional Ownership by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.